Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,742 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Formulation #2 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole

NCT04139226
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-11050
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 31, 2026, 3:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS)

NCT02597634
View directory record Official record
Conditions
Delayed Onset Muscle Soreness, DOMS
Interventions
SST-0225, Placebo
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
16 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Hollywood, Florida • South Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Oct 31, 2026, 3:20 AM EDT
Terminated Phase 2 Interventional

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

NCT00117884
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
851B
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
22
States / cities
Colton, California • San Diego, California • Colorado Springs, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Oct 31, 2026, 3:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants

NCT03765073
View directory record Official record
Conditions
Group B Streptococcus Infections
Interventions
Multivalent Group B streptococcus vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Years to 40 Years
Enrollment
1,208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
26
States / cities
Mobile, Alabama • Phoenix, Arizona • Lancaster, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 31, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)

NCT06609161
View directory record Official record
Conditions
Healthy
Interventions
Tedizolid Phosphate Oral Formulation 1 (Reference), Tedizolid Phosphate Oral Formulation 2 (Test)
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 31, 2026, 3:20 AM EDT
Completed Not applicable Interventional

Cognitive Behavioral Social Skills Training for Improving Social Functioning in People With Schizophrenia

NCT00338975
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive Behavioral Social Skills Training (CBSST), Goal-focused supportive contact (GFSC), Social Skills Training, Goal Setting
Behavioral
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 31, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults

NCT07226362
View directory record Official record
Conditions
Safety, and Tolerability
Interventions
DHE inhalation powder low dose administered via dry powder inhaler (DPI) device, DHE inhalation powder high dose administered via dry powder inhaler (DPI) device, DHE injected intravenously (1 mg), DHE 2 mg administered by nasal spray (Migranal®), Metoclopramide 10mg
Combination Product · Drug
Lead sponsor
Aspeya Switzerland SA
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 31, 2026, 3:20 AM EDT
Recruiting Phase 2 Interventional

Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI

NCT04550377
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Traumatic Brain Injury
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 31, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Bioequivalence of Single Oral Dose of Esomeprazole Capsule and Tablet Formulation in Healthy Participants

NCT03083639
View directory record Official record
Conditions
Healthy Participants
Interventions
Esomeprazole Capsule, Esomeprazole Tablet
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 31, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147

NCT05955872
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis (FSGS)
Interventions
VX-147
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 31, 2026, 3:20 AM EDT
Not listed Not applicable Interventional

"Hyaluronan" Formulation for Dry Mouth in Sleep Apnea Patients

NCT03295019
View directory record Official record
Conditions
Dry Mouth, Xerostomia, OSA, Sleep Apnea
Interventions
Test Oral Spray, Placebo Oral Spray
Device
Lead sponsor
You First Services
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 31, 2026, 3:20 AM EDT
Completed Phase 2 Interventional

A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)

NCT00240929
View directory record Official record
Conditions
-Unhealthy Children With a History of Prematurity
Interventions
MEDI-493
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
5 Months to 6 Months
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2010 · Synced Oct 31, 2026, 3:20 AM EDT
Completed Phase 3 Interventional Results available

Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection

NCT00098059
View directory record Official record
Conditions
Herpes Simplex
Interventions
Famciclovir
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 12 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
11
States / cities
Birmingham, Alabama • Denver, Colorado • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Oct 31, 2026, 3:20 AM EDT
Completed Phase 3 Interventional Results available

Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

NCT00478205
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aricept (donepezil SR 23 mg), Aricept (donepezil IR 10 mg)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
1,467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 31, 2026, 3:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine

NCT02222870
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® Quadrivalent Influenza Vaccine, No Preservative
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 8 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 31, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions

NCT00863941
View directory record Official record
Conditions
Healthy
Interventions
Abrika Bupropion 150 mg XL Tablet, single dose, Wellbutrin XL® 150 mg Tablet, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2010 · Synced Oct 31, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting Conditions

NCT01448772
View directory record Official record
Conditions
Bioavailability
Interventions
Dronabinol Capsules, 5 mg, Dronabinol Oral Solution
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Oct 31, 2026, 3:20 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease

NCT00559871
View directory record Official record
Conditions
Parkinson's Disease
Interventions
fipamezole
Drug
Lead sponsor
Juvantia Pharma Ltd
Industry
Eligibility
30 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
29
States / cities
Birmingham, Alabama • Northport, Alabama • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Oct 31, 2026, 3:20 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity

NCT06830863
View directory record Official record
Conditions
EGFR Inhibitor-associated Rash
Interventions
ATR04-484, Vehicle
Drug
Lead sponsor
Azitra Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Hot Springs, Arkansas • New Haven, Connecticut • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 3:20 AM EDT
Completed Phase 2 Interventional Results available

Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy

NCT03176472
View directory record Official record
Conditions
Painful Diabetic Peripheral Neuropathy
Interventions
ricolinostat, Placebo
Drug
Lead sponsor
Regenacy Pharmaceuticals LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
35
States / cities
Anniston, Alabama • Phoenix, Arizona • Huntington Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 31, 2026, 3:20 AM EDT
Completed Phase 1 Interventional

Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation

NCT01647659
View directory record Official record
Conditions
Cancer
Interventions
Trametinib tablet, Trametinib pediatric formulation
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Scottsdale, Arizona • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 31, 2026, 3:20 AM EDT
Not listed Phase 2 Interventional

MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)

NCT04874506
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
MBM-02
Drug
Lead sponsor
Matrix Biomed, Inc.
Industry
Eligibility
35 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 31, 2026, 3:20 AM EDT
Completed Phase 2 Interventional Results available

Study of Buprenorphine HCl Buccal Film in the Treatment of Dental Pain

NCT00941304
View directory record Official record
Conditions
Dental Pain
Interventions
Oxycodone, Buprenorphine, Placebo Film, Placebo Capsule
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 45 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Austin, Texas • San Marcos, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 31, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

NCT00902681
View directory record Official record
Conditions
Treatment of Overactive Bladder
Interventions
Fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 31, 2026, 3:20 AM EDT